In hepatoma, colon carcinoma, pancreatic cancer and primary human esthesioneuroblastoma cells, Bortezomib-mediated sensitization to TRAIL, within the therapeutic window, has been demonstrated to be mediated by enhanced TRAIL DISC formation, heightened caspase-8 presence and cFLIPL downregulation at the DISC and upregulation of TRAIL-R1/TRAIL-R2 [116–118]. Here, TNFSF10 is linked to familial pancreatic carcinoma.